INSTITUTE OF INDUSTRIAL SCIENCE, THE UNIVERSITY OF TOKYO IMAGE: RESEARCHERS FROM THE INSTITUTE OF INDUSTRIAL SCIENCE, THE UNIVERSITY OF TOKYO HAVE DEVELOPED A STREAMLINED PHOTO-UNCAGING SYSTEM FOR PHOTODYNAMIC CANCER THERAPY, USING A PULSE OF LIGHT FOR TUMOR-SPECIFIC ACTIVATION OF A CANCER-FIGHTING AGENT CREDIT: INSTITUTE OF INDUSTRIAL SCIENCE, THE UNIVERSITY OF TOKYO Tokyo, Japan – One...
TOKYO UNIVERSITY OF SCIENCE VIDEO: SCIENTISTS ELUCIDATE THE REGULATORY MECHANISMS UNDERLYING “AUTOPHAGY” MEDIATED COMPETITIVE ELIMINATION OF CANCER CELLS. CREDIT: TOKYO UNIVERSITY OF SCIENCE The maintenance of a healthy cell population is a dynamic process, whereby unhealthy cells are eliminated by a defense mechanism called “cell competition”. This process is crucial as unhealthy cells or cells...
Hilary Brueck Blood samples taken from a patient receiving CAR-T immunotherapy. AP Photo/Elaine Thompson A half dozen patients in Germany have been functionally cured of lupus — for now, at least. Their doctors used a blood-engineering technique that’s usually reserved for fighting aggressive cancers (CAR-T). It’s unlikely that such a technique could become widespread for lupus-sufferers,...
A type of cancer treatment known as CAR T therapy has shown great promise for blood cancer treatments in the last decade, but too often, patients relapse within a short time. Now, a team of researchers has uncovered some critical clues about why – potentially leading to treatments to prevent these relapses. CAR T therapy involves isolating...
by H. Lee Moffitt Cancer Center & Research Institute LAG3 Crystal Structure. Credit: Moffitt Cancer Center Immune checkpoint inhibitors have revolutionized cancer care. The therapy works by preventing tumors from shutting down the immune response, which in turn allows T cells to kill cancer cells. Established checkpoint inhibitors target the proteins PD-1 and CTLA-4 and...
by Walter and Eliza Hall Institute of Medical Research Learning the rules for programming self-associating membrane proteins (MPs). (a) Rosetta fold, dock, and design uses backbone fragments from natural MPs to construct symmetric, de novo architectures and an MP energy function (Weinstein et al., 2019) to optimize the amino acid sequence. (b) Round 1 designs...
by University Hospitals Cleveland Medical Center Reduced tumor sizes by FDG-PET imaging reflected in the red signal next to yellow arrows, in 6 mice receiving ivosidenib (AG-120) compared to control mice without drug. Credit: University Hospitals A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme,...
by Institute for Basic Science Figure 1. Cancer cells tend to accumulate many mutations during their growth. These include single base substitutions, small insertion/deletions (InDel), and large chromosomal changes. Researchers made CRISPR-Cas9 reagents targeting tumor-specific InDel mutations that can induce numerous double-strand breaks in the DNA of cancer cells, effectively killing them. Because normal cells...
by Liz Fuller-Wright, Princeton University In mice and in human tissue, a new compound discovered by Yibin Kang, seen here in his lab in 2017, disables a key gene that’s implicated in breast, prostate, liver, lung, colon and other cancers. Credit: Denise Applewhite, Office of Communications Imagine you could cure cancer by targeting one tiny gene....
by Karolinska Institutet Graphical abstract. Credit: DOI: 10.1016/j.redox.2021.102184 The gold complex auranofin has traditionally been used for treating rheumatism but is also being evaluated as a treatment for certain forms of cancer. Researchers at Karolinska Institutet in Sweden now show that other molecules that inhibit the same biological system have a more specific effect than auranofin...
